Clinical Trial Update: A Study of Efficacy and Safety of TLL-018 in CSU Participants [Phase 3]

View source ↗

Summary

Phase 3 study update on the efficacy and safety of TLL-018 in chronic spontaneous urticaria (CSU) is currently active, not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spontaneous Urticaria

Drugs mentioned

• TLL-018

Snippet

Sponsor: Hangzhou Highlightll Pharmaceutical Co., Ltd | Conditions: Chronic Spontaneous Urticaria | Phase 3 | Status: ACTIVE_NOT_RECRUITING